CoagulationDisorders near Hackensack, NJ

Biography: Jones Nauseef, M.D., Ph.D., is an Assistant Professor of Medicine within the Division of Hematology and Medical Oncology at Weill Cornell Medicine, and Assistant Attending physician at NewYork-Presbyterian Hospital. His clinical emphasis is on Genitourinary (GU) cancers and Phase I clinical trials. His research is focused on genomics of advanced prostate cancers, including neuroendocrine prostate cancer, as well as health care disparities.Dr. Nauseef received his B.A. in Biology in 2006 from Swarthmore College, where he also participated in NCAA Track and Cross Country. In 2015, Dr. Nauseef earned his M.D. and Ph.D. in Molecular Physiology and Biophysics (Laboratory of Dr. Michael D. Henry) as part of the NIH-sponsored MedicalScientist Training Program (MSTP) at the Carver College of Medicine of theUniversity of Iowa. He continued his medical training at Weill Cornell Medicine and NewYork-Presbyterian (WCM/NYP), where he completed his Internship and Residency in Internal Medicine in 2018. He was honored to be the recipient of the David B. Skinner award at the conclusion of his residency. He remained at WCM/NYP for his Fellowship in Hematology and Medical Oncology, during which time he was awarded a 2020 Conquer Cancer Foundation of ASCO Young Investigator Award (YIA) and the 2021 Scott Wadler Fellows Clinical Research Award. During his Fellowship, Dr. Nauseef expanded his research focus to include the genomics of advanced prostate cancers and health care disparities in American men of African descent. He serves as co-investigator or collaborator on extramural grants for the latter project. Dr. Nauseef will continue these investigations as a member of the Englander Institute for Precision Medicine and inaffiliation with the New York Genome Center, with the primary goal of leveraging discoveries to develop clinical trials as part of the Phase I/Earlytherapeutics group at Weill Cornell's Meyer Cancer Center.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Care Philosophy: I am a medical oncologist with interests in lung cancers, head and neck cancers, and pancreatic cancers. Its important to me that patients feel they are not alone in their fight against cancer. I have a strong interest in clinical trial and providing patients with the most advanced available care. My goal is to help patients be in control with their health and understand their treatment options.

Biography: Dr. Ronald Hoffman, MD is an Anatomic /amp Clinical Pathology Specialist who practices in New York, NY. He is 80 years old and has been practicing for 54 years. Dr. Ronald Hoffman, MD is affiliated with Mount Sinai Hospital.

Biography: Benjamin Samstein, MD is Chief of Liver Transplantation and Hepatobiliary Surgery in the Department of Surgery at NewYork-Presbyterian/Weill Cornell Medicine and Associate Professor of Surgery at Weill Cornell Medical College, Cornell University. Dr. Samstein is the Surgical Director of the Living Donor Liver Transplant Program at NYP. Dr. Samstein is a renowned pioneer in minimally invasive liver surgery and state-of-the-art laparoscopic techniques for liver cancer. Dr. Samstein is a Castle Connolly Top Doctor. Dr. Samstein heads up the multidisciplinary liver transplantation and hepatobiliary surgery team at NYP/Weill Cornell. His specialties include the most advanced laparoscopic procedures for liver cancer, benign liver tumors and hepatobiliary pancreatic disease. He has been invited to talk about minimally invasive liver surgery throughout the world. He is a member of many surgical societies including a founding member of the International Laparoscopic Liver Society (ILLS), American Society of Transplant Surgery, American Hepato-Pancreato-Biliary Association (AHPBA). He is the Chair of the Medical Advisory Board of LiveOnNY and served as the Regional representation to the Liver and Intestine Committee of UNOS from 2014 to 2016. Dr. Samstein is well-published in the field, authoring more than 40 peer-reviewed articles in prestigious medical and surgical journals, books and book chapters. Other areas of clinical expertise include hepatic adenoma, hepatic hemangioma, cholangiocarcinoma, colorectal metastasis, live donor nephrectomy, laparoscopic living donor nephrectomy, and pediatric liver and organ transplant. Dr. Samstein received his undergraduate degree from Cornell University in 1992 and earned his MD at the State University of New York at Stonybrook in 1997. He did his internship and residency in general surgery at NYP/Columbia, and completed a research fellowship at the Mayo Clinic in 2001. He completed a fellowship in ASTS Multi-organ transplant at NYP/Columbia in 2006. He was Assistant Professor of Surgery at Columbia University Medical Center from 2006 to 2015. He served as Program Director of the transplant surgery fellowship at Columbia University from 2007 to 2015. He is a reviewer for American Journal of Transplantation, Transplantation, Liver Transplantation, Pediatric Transplantation, Clinical Transplantation among other journals. List of Publications by Dr. Samstein PubMed

Biography: Dr. Amengual is the Herbert Irving Associate Professor of Medicine in the Division of Hematology and Oncology, Center for Lymphoid Malignancies, and Hebert Irving Comprehensive Cancer Center here at Columbia University Irving Medical Center. Dr. Amengual obtained a degree in Nutritional Sciences at Cornell University where she graduated with honors. She attained her Medical Doctorate from New York Medical College, followed by a residency in Internal Medicine at Montefiore Medical Center/Albert Einstein College of Medicine. Dr. Amengual then went on to complete her fellowship in Hematology and Oncology at the NYU Langone Medical Center, where she participated in the Physician-Scientist Training Program and graduated as a Dean's Scholar. She is the recipient of several awards and scholarships for her research, including the Irving Scholarship, the Gabrielle's Angel Foundation for Cancer Research and as a Scholar of the Amos Medical Faculty Development Award Robert Wood Johnson Foundation and the American Society of Hematology. She was also selected to participate in the prestigious American Association for Cancer Research (AACR)/American Society of Clinical Oncology (ASCO) Vail Workshop Methods in Clinical Cancer Research, the European Hematology Association/American Society of Hematology Translational Research Training Program and the South West Oncology Group (SWOG) Leadership Academy. These competitive programs select the most promising faculty for enriched development and have laid the foundation for her research. She has now served on the faculty or review committee of several of these programs. As an R01-funded physician-scientist, Dr. Amengual is focused on translating the latest scientific discoveries regarding cancer cell behavior into novel treatment platforms. She aims to translate observations and concepts developed in the laboratory directly into patient care. Specifically, she is focused on combination epigenetic targeting for both B-cell and T-cell lymphomas. She continues to develop new pharmacologic strategies directed at altering these diseases at their genetic roots, now collaborating with investigators from backgrounds of diverse scientific expertise. Dr. Amengual has been studying the effects HDAC inhibitors in combination with EZH2 inhibitors to capitalize on two common mutations driving growth of diffuse large B-cell lymphoma cells. In addition, she has studied targeting the BCL6:p53 pathway in order to shift the balance of oncogene and tumor suppressor function using novel therapeutic approaches. For T-cell lymphoma Dr. Amengual has led a clinical trial combining HDAC inhibitors with the novel antifolate drug, pralatrexate. The pralatrexate plus romidepsin combination has led to dramatic responses in patients with relapsed T-cell lymphoma and will serve as the basis of more trials to come aimed at improving outcomes with patients with these diseases. Building on these discoveries, Dr. Amengual is now evaluating the interplay of epigenetics with immune surveillance and endogenous retroviral expression in the setting of lymphoma. Dr. Amengual has lectured at academic institutions and conferences around the world, and at forums such as the Lymphoma Research Foundation and the American Hematology Society's Highlights of ASH. She has published numerous chapters and peer reviewed articles on the biology and treatment of lymphoma, and serves as a Scientific Reviewer for a number of journals in the field, including Journal of Clinical Oncology and as an Editorial Board Member of Clinical Cancer Research. She has sat on grant review and abstract review committees for meetings such as the American Society of Hematology where she has also chaired sessions, American Society of Clinical Oncology and the Doris Duke Charitable Foundation. She is actively involved in the NCI's National Clinical Trial Network, SWOG, as a Lymphoma Working Group Committee Member. Dr. Amengual is involved in numerous clinical trials for lymphoma, enabling our patients to access the best opportunities for the treatment of their disease. Dr. Amengual has clinical expertise in lymphoma, HIV- and EBV-related hematologic illnesses.